NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
Clinical Trials
33 trialsNCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05037500 2025-11-12
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT05588609 2025-09-18
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Merus B.V.
Phase 2 Terminated
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT03300505 2025-05-13
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05075577 2025-02-28
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
ESSA Pharmaceuticals
Phase 1/2 Terminated
NCT03177187 2024-09-26
ACE
Institute of Cancer Research, United Kingdom
Phase 1/2 Terminated
NCT03869762 2024-09-25
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT03850795 2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
Phase 3 Terminated
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04844749 2024-02-05
VERACITY
Veru Inc.
Phase 3 Terminated
NCT04409288 2024-01-05
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong
Phase 3 Terminated
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT02640534 2023-06-27
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Swiss Cancer Institute
Phase 2 Terminated
NCT02438007 2023-03-15
ARMOR3-SV
LTN PHARMACEUTICALS, INC.
Phase 3 Terminated
NCT04142060 2022-10-28
ARIANNA
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT02457910 2022-08-22
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT03531827 2022-07-12
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04052204 2021-10-14
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT02508636 2021-10-12
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02489123 2021-08-10
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT03829930 2021-08-02
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
George Washington University
Phase 1 Terminated
NCT03478904 2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02685267 2021-04-09
Doce/Enza
Prostate Cancer Clinical Trials Consortium
Phase 2 Terminated
NCT02607228 2020-12-08
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT02500901 2019-10-21
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Hoosier Cancer Research Network
Phase 1 Terminated
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT02491411 2018-07-12
DEXTER
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated
NCT02441517 2018-04-19
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
Astellas Pharma Inc
Phase 4 Terminated